Payment overview · 2025
General Payments
$106.74
6 reported records · 4 companies
Healthcare provider profile · identity verified
Deepa Retnem Potti, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WINSTON SALEM, NC · NPI 1144206301
Verified facts
What the public records show
CMS Open Payments records show Deepa Retnem Potti, M.D. received $106.74 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 34.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.24 | 34.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.45 | 29.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.56 | 20.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.49 | 16.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $106.74 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.56 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
113 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 585 | 180 |
| Levothyroxine Sodium | Levothyroxine Sodium | 533 | 153 |
| Amlodipine Besylate | Amlodipine Besylate | 389 | 129 |
| Alprazolam | Alprazolam | 379 | 94 |
| Losartan Potassium | Losartan Potassium | 372 | 113 |
| Lisinopril | Lisinopril | 364 | 116 |
| Hydrochlorothiazide | Hydrochlorothiazide | 322 | 97 |
| Gabapentin | Gabapentin | 315 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 299 | 75 |
| Omeprazole | Omeprazole | 277 | 86 |
| Simvastatin | Simvastatin | 275 | 89 |
| Escitalopram Oxalate | Escitalopram Oxalate | 265 | 55 |
| Metformin Hcl Er | Metformin Hcl | 251 | 78 |
| Trazodone Hcl | Trazodone Hcl | 228 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 225 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 215 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 203 | 63 |
| Eliquis | Apixaban | 196 | 43 |
| Furosemide | Furosemide | 189 | 65 |
| Fluticasone Propionate | Fluticasone Propionate | 183 | 82 |
| Ezetimibe | Ezetimibe | 176 | 50 |
| Famotidine | Famotidine | 168 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 167 | 47 |
| Metformin Hcl | Metformin Hcl | 159 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 150 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 62 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 145 | 49 |
| Januvia | Sitagliptin Phosphate | 145 | 30 |
| Jardiance | Empagliflozin | 138 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 134 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 127 | 40 |
| Atenolol | Atenolol | 116 | 33 |
| Allopurinol | Allopurinol | 114 | 38 |
| Ozempic | Semaglutide | 113 | 30 |
| Alendronate Sodium | Alendronate Sodium | 111 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 108 | 27 |
| Meloxicam | Meloxicam | 107 | 41 |
| Montelukast Sodium | Montelukast Sodium | 107 | 36 |
| Clonazepam | Clonazepam | 106 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 103 | 87 |
| Cephalexin | Cephalexin | 98 | 69 |
| Fluconazole | Fluconazole | 97 | 42 |
| Potassium Chloride | Potassium Chloride | 97 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 97 | 17 |
| Glipizide | Glipizide | 95 | 22 |
| Lorazepam | Lorazepam | 95 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 93 | 28 |
| Glimepiride | Glimepiride | 93 | 30 |
| Sertraline Hcl | Sertraline Hcl | 90 | 25 |
| Diazepam | Diazepam | 86 | 22 |
| Carvedilol | Carvedilol | 84 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 84 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 21 |
| Bupropion Xl | Bupropion Hcl | 75 | 25 |
| Promethazine Hcl | Promethazine Hcl | 74 | 16 |
| Finasteride | Finasteride | 73 | 24 |
| Warfarin Sodium | Warfarin Sodium | 73 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 19 |
| Fenofibrate | Fenofibrate | 70 | 22 |
| Tramadol Hcl | Tramadol Hcl | 68 | 24 |
| Xarelto | Rivaroxaban | 66 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 64 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 42 |
| Valacyclovir | Valacyclovir Hcl | 59 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 58 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 51 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | 13 |
| Amoxicillin | Amoxicillin | 55 | 44 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 17 |
| Buspirone Hcl | Buspirone Hcl | 52 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 52 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | 16 |
| Methylprednisolone | Methylprednisolone | 50 | 43 |
| Glipizide Er | Glipizide | 49 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 14 |
| Mupirocin | Mupirocin | 49 | 36 |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Irbesartan | Irbesartan | 46 | 11 |
| Trulicity | Dulaglutide | 46 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Prednisone | Prednisone | 43 | 36 |
| Donepezil Hcl | Donepezil Hcl | 42 | 14 |
| Pregabalin | Pregabalin | 42 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 19 |
| Ibuprofen | Ibuprofen | 38 | suppressed |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 33 |
| Spironolactone | Spironolactone | 36 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Nystatin | Nystatin | 35 | 23 |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Verapamil Er | Verapamil Hcl | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 22 |
| Celecoxib | Celecoxib | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | 11 |
| Lidocaine | Lidocaine | 25 | 14 |
| Alcohol Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 18 |
| Ramipril | Ramipril | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 15 |
| Linzess | Linaclotide | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 11 |
| Nystop | Nystatin | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Glyburide | Glyburide | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $106.74 · 6 records | Novo Nordisk Inc | AIRSUPRA, CAPVAXIVE, ENFLONSIA, FARXIGA, GARDASIL 9, ROTATEQ, The Cologuard Plus Collection Kit, VAXNEUVANCE, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error